niftify.in

Business Standard

Granules India Ltd drops for fifth straight session

Granules India Ltd is quoting at Rs 549.15, down 0.14% on the day as on 13:19 IST on the NSE. The stock jumped 67.99% in last one year as compared to a 26.25% rally in NIFTY and a 51.14% spurt in the Nifty Pharma index.

The Economic Times

Granules India shares tank 16% after USFDA issues 6 observations

Granules India’s shares plummeted 16% to Rs 566 on Thursday after receiving six observations from the USFDA, including issues with equipment cleanliness and quality control procedures. Over 3 crore shares traded as investors reacted to the news.

Business Standard

Granules India tumbles after Hyderabad facility gets six observations from USFDA

Granules India dropped 15.90% to Rs 570 after US Food and Drug Administration (USFDA) concluded its inspection at Gagillapur facility, in Hyderabad with six observations.

Business Standard

Granules India Ltd leads losers in 'A' group

Prism Johnson Ltd, R R Kabel Ltd, TCI Express Ltd and Raymond Ltd are among the other losers in the BSE's 'A' group today, 12 September 2024.

Business Standard

Granules tanks 16% on concerns over 6 observations issued by US FDA

More than 31 million equity shares, representing 12.89 per cent equity of the pharmaceutical company, had changed hands on the NSE till 02:08 PM.

Mint

Granules India shares plunge 16% after USFDA inspection ends with 6 observations

Granules India shares fell over 16% on September 12 after the USFDA inspection revealed six observations. The company reassured investors of its commitment to address the issues and uphold quality standards while promising timely updates.

The Economic Times

Aditya Agarwala suggests a fresh long position in Bank Nifty; recommends 2 stocks to buy

Aditya Agarwala of Invest4edu suggests initiating a long position in Bank Nifty, targeting 51,700 to 52,000. He also recommends buying Britannia and Apollo Hospitals. While cautioning against Granules, he sees potential in Kaynes Technology. The market remains range-bound with key support at 24,900 and resistance at 25,100. Agarwala also says that one should monitor a trade above 25,100 on a sustained basis for any kind of short-covering rally.

CNBC TV18

Granules India shares fall 15% on concerns over 6 USFDA observations to the Gagilapur unit

The USFDA has also pointed out to a repeat observation from the company’s Jan 2023 inspection.

Business Standard

USFDA issues six observations for Granules' Gagillapur unit; stock falls 5%

The fall in Granules India share price came after the company announced that United States Food and Drug Administration (USFDA) has issued six observations for the company's Gagillapur facility.

CNBC TV18

Granules India's Gagillapur facility completes US FDA inspection with 6 observations

Shares of Granules India Ltd ended at ₹687.50, down by ₹10.30, or 1.48% on the BSE.

CNBC TV18

Top stock picks | Metropolis, Hindustan Copper, TVS Motors, Granules and NTPC on the radar

On Monday, market tech analysts Aditya Agarwala, Soni Patnaik, Mitessh Thakkar and F&O analyst Chandan Taparia recommended these stocks for the short term.

Business Standard

F&O Cues: Options data hint more gains for Nifty; 4 stocks see long buildup

Derivative market update for Monday, Sept 02: FIIs long-short ratio in index futures rose to 2.6:1, implying 5 longs for every 2 shorts. Bandhan Bank, Syngene and Granules India see long buildup.

CNBC TV18

Granules India shares fall after surprise inspection at a key facility: Exclusive

Currently, 11 Abbreviated New Drug Applications (ANDAs) filed and pending for the US markets out of the 16 pending ANDAs are from this facility. So far, 36 ANDAs have been approved from this facility.

Business Line

Granules India secures US FDA approval for Trazodone tablets

This approval brings Granules’ total FDA approvals to 65, including 64 final approvals and one tentative approval